Acetamide derivative having defined particle size

Inactive Publication Date: 2002-01-15
CEPHALON INC
View PDF23 Cites 74 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"An effective amount", as used herein, is an amount of the pharmaceutical composition that is effective for treating a somnolent or somnolescent state, i.e., an amount of modafinil of a defined particle size that i

Problems solved by technology

Pathological somnolence, whether due to narcolepsy or other causes, is disabling and potentially dangerous.
Whether due to narco

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acetamide derivative having defined particle size

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

We first briefly describe the drawings.

I. Drawings

FIG. 1 is a graph depicting particle size distributions for six lots of modafinil: Lots L-1, L-2, E-A, E-B, E-C and E-D.

FIG. 2 is a scanning electron micrograph of a sample of modafinil Lot E-D at 50.times. magnification.

FIG. 3 is a scanning electron micrograph of a sample of modafinil Lot E-D at 100.times. magnification.

FIG. 4 is a scanning electron micrograph of a sample of modafinil Lot L-1 at 50.times. magnification.

FIG. 5 is a scanning electron micrograph of a sample of modafinil Lot L-1 at 100.times. magnification.

FIG. 6 is a graph depicting the dissolution rate of modafinil particles from Lot E-D (median particle size 94.05 .mu.m) and Lot L-1 (median particle size 50.18 .mu.m).

FIG. 7 is a graph depicting the dissolution rate of modafinil particles from Lot E-B (median particle size 89.10 .mu.m), Lot E-D (median particle size 94.05 .mu.m) and Lot L-1 (median particle size 50.18 .mu.m).

FIG. 8 is a graph depicting mean plasma con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Size distributionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Pharmaceutical compositions comprising modafinil in the form of particles of defined size. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.

Description

BACKGROUND OF THE INVENTIONPublications cited in this document are incorporated herein by reference.This invention relates to the acetamide derivative modafinil. Modafinil (C.sub.15 H.sub.15 NO.sub.2 S), is 2-(benzhydrylsulfinyl)acetamide, and is also known as 2-[(diphenylmethyl)sulfinyl]acetamide.Modafinil has been described as presenting a "neuropsychopharmacological spectrum characterized by the presence of excitation with hyperactivity and of hypermotility; and by the absence of stereotypy (except in high doses) and of potentialisation of the effects of apomorphine and amphetamine" (U.S. Pat. No. 4,177,290; hereinafter the "'290 patent," which is incorporated herein by reference). A single administration of modafinil results in increased locomotor activity in mice and increased nocturnal activity in monkeys (Duteil et al., Eur. J. Pharmacol. 180:49 (1990)). The neuropsychopharmacological profile of modafinil has been distinguished from that of amphetamines (Saletu et al., Int. J...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/14A61K31/165A61K9/16A61K31/16A61P25/00A61P25/24A61P25/26A61P25/28
CPCA61K9/14A61K9/16A61K31/165A61P25/00A61P25/24A61P25/26A61P25/28
Inventor GREBOW, PETER E.CORVARI, VINCENTSTONG, DAVID
Owner CEPHALON INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap